Investor Insights- Full ReportPublished: February 7, 2020
The regenerative medicine sector is going through a phase of significant growth. Thousands of patients are now benefitting from commercial regenerative medicines, and the impact of the early cell and gene therapies is dramatic. The clinical pipeline is robust, with nearly a hundred Phase 3 trials underway, several late-stage products poised for approval, and next-gen technologies such as gene editing beginning to enter the clinic. The sector continue to attract billions in investment, further fueling the scientific, clinical and commercial progress.
You can download this month’s Investor Insights report free of charge – simply login or register here to become a member